Darbepoetin alfa biosimilar (Nanogen)

阿法达贝泊汀生物类似药 (Nanogen)

Report date: 2022/10/20 20:01:22

Base Information

Drug NameDarbepoetin alfa biosimilar (Nanogen)
Drug Alias NameStimus (NNG-DEPO)Darbatitor
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryVietnam
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNanogen Pharmaceutical Biotechnology Joint Stock Company
China Registration ClassN/A

Develop Information

Active CompaniesNanogen Pharmaceutical Biotechnology Joint Stock Company
Inactive CompaniesN/A
Active IndicationsAnemiaRenal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A